ViroGates マネジメント

マネジメント基準チェック /24

ViroGatesの CEO はJakob Knudsenで、 Apr2011年に任命され、の在任期間は 13.58年です。は、会社の株式の1.62%を直接所有しており、その価値はDKK 1.93M 。経営陣と取締役会の平均在任期間はそれぞれ6.7年と2.6年です。

主要情報

Jakob Knudsen

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	13.6yrs
CEOの所有権	1.6%
経営陣の平均在職期間	6.7yrs
取締役会の平均在任期間	2.6yrs

経営陣の近況

Recent updates

CEO報酬分析

ViroGates の収益と比較して、Jakob Knudsen の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-DKK 13m
Jun 30 2024	n/a	n/a	-DKK 13m
Mar 31 2024	n/a	n/a	-DKK 13m
Dec 31 2023	n/a	n/a	-DKK 12m
Sep 30 2023	n/a	n/a	-DKK 11m
Jun 30 2023	n/a	n/a	-DKK 11m
Mar 31 2023	n/a	n/a	-DKK 10m
Dec 31 2022	DKK 2m	DKK 1m	-DKK 10m
Sep 30 2022	n/a	n/a	-DKK 12m
Jun 30 2022	n/a	n/a	-DKK 13m
Mar 31 2022	n/a	n/a	-DKK 16m
Dec 31 2021	DKK 2m	DKK 1m	-DKK 18m
Sep 30 2021	n/a	n/a	-DKK 18m
Jun 30 2021	n/a	n/a	-DKK 18m
Mar 31 2021	n/a	n/a	-DKK 17m
Dec 31 2020	DKK 2m	DKK 1m	-DKK 19m

報酬と市場: Jakobの総報酬がDanish市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Jakobの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jakob Knudsen (56 yo)

13.6yrs

在職期間

DKK 1,601,492

報酬

Mr. Jakob Knudsen serves as Independent Director at ExpreS2ion Biotech Holding AB (publ) since 2021. He had been Director at ExpreS2ion Biotech Holding AB (publ) since April 19, 2017 until 2021. Mr. Knudse...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jakob Knudsen	Chief Executive Officer	13.6yrs	DKK 1.60m	1.62% DKK 1.9m
Jesper Eugen-Olsen	Co-Founder & Chief Scientific Officer	24.8yrs	データなし	3.37% DKK 4.0m
Josephine Jorgensen	Chief Financial Officer	1.7yrs	データなし	0.016% DKK 18.5k
May Dyvelkov	Vice President of Accounting	5.1yrs	データなし	データなし
Thomas Krarup	Vice President of Global Sales & Marketing	6.7yrs	データなし	0.21% DKK 248.2k
David Poulsen	Head of Marketing	no data	データなし	データなし

6.7yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: VIROの経営陣は経験豊富で経験豊富です（平均在職期間は6.7年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Peter Aaby	Scientific Advisor	no data	データなし	データなし
Lars Kongsbak	Non-Executive Director	no data	DKK 106.25k	0.090% DKK 107.3k
Knut Borch-Johnsen	Scientific Advisor	17.8yrs	データなし	データなし
Patrik Dahlen	Independent Chairman	2.6yrs	データなし	0.14% DKK 162.8k
Valerie Soulier	Independent Director	2.6yrs	DKK 87.85k	データなし

2.6yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: VIROの取締役会は経験豊富ではない ( 2.6年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

ViroGates マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

ViroGates A/S Announces Chief Financial Officer Changes

ViroGates A/S Announces Executive Changes

High number of new directors

ViroGates A/S Announces Board Changes

Recent updates

Third quarter 2024 earnings released

New major risk - Revenue size

ViroGates A/S Maintains Earnings Guidance for the Full-Year of 2024

Second quarter 2024 earnings released

First quarter 2024 earnings released

Full year 2023 earnings released

ViroGates A/S to Report Fiscal Year 2023 Results on Mar 21, 2024

New major risk - Shareholder dilution

ViroGates A/S has filed a Follow-on Equity Offering in the amount of DKK 15.077282 million.

Third quarter 2023 earnings released

ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis

Virogates Provides Earnings Guidance for 2023

Second quarter 2023 earnings released

New major risk - Market cap size

First quarter 2023 earnings released

Full year 2022 earnings released

ViroGates (CPH:VIRO) Is In A Good Position To Deliver On Growth Plans

ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms

ViroGates A/S Announces Chief Financial Officer Changes

ViroGates A/S to Report Fiscal Year 2022 Results on Mar 23, 2023

ViroGates A/S Announces Executive Changes

We're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely

ViroGates A/S Announces the Publication of A New Study That Shows SsuPAR upar Causes Cardiovascular Disease

ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform

Second quarter 2022 earnings released

ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023

Will ViroGates (CPH:VIRO) Spend Its Cash Wisely?

High number of new directors

ViroGates A/S Announces Board Changes

ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+

First quarter 2022 earnings released

ViroGates A/S announces successful finalization of the development project with DIESSE Diagnostica Senese S.p.A

Third quarter 2021 earnings released

We're Not Very Worried About ViroGates' (CPH:VIRO) Cash Burn Rate

Second quarter 2021 earnings released

ViroGates A/S and the Hellenic Institute for the Study of Sepsis Announce Positive Top-Line Results from the Save-More Study

First quarter 2021 earnings released: kr.1.37 loss per share (vs kr.2.04 loss in 1Q 2020)

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

ViroGates A/S Announces Clinical Routine Use in Greece

New 90-day high: kr.94.00

ViroGates A/S Announces a New Private Hospital as Clinical Routine Customer in Spain

ViroGates A/S Announces Initiation of A Clinical Trial with Hiss to Clinically Validate Its Commercial Biomarker Test for Guiding Early Anakinra Treatment of Covid-19 Patients Across 42 Hospitals

ViroGates A/S Announces Delay in the Development and Launch of suPARnostic POC+ Product

We Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth

ViroGates A/S to Report Q3, 2021 Results on Nov 11, 2021

ViroGates A/S to Report Q2, 2021 Results on Aug 19, 2021

ViroGates Announces Receipt of the First Order from Mikkeli Central Hospital in Finland

New 90-day high: kr.67.50

Third quarter earnings released

Virogates Announces Receipt of A First Order from the University Hospital of Salamanca, A New Clinical Routine Customer in Spain

New 90-day low - kr.57.00

First half earnings released

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24